Outcomes, quality of life, and costs of different treatment modalities of coronary artery disease.
What is it about?
In the transition towards value based health care there is a growing interest in health gains of treatment assessed by patient reported outcomes (PROs) such as health related quality of life (HRQoL). Our study showed no statistically significant differences between the patient groups in 8-year survival or change in HRQoL among survivors. The 8-year mean secondary care costs of CABG were over two-fold and almost four-fold, even after adjustment for baseline characteristics, compared with those of PCI and MT.
Why is it important?
Patient involvement and conduction of observational trials in routine care can make information on quality and treatment outcomes more accessible for patients as end users.
The following have contributed to this page: MD Harriet Stenvall